Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (61-70 of 277) with videos related to

Pageof 28
Sort By:
Plos One|August 15, 2014
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsYunyun Jiang, Vivek Subbiah, Filip Janku, et al.
Investigational New Drugs|April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerFilip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Cold Spring Harbor Molecular Case Studies|August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumorsShiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
Investigational New Drugs|February 15, 2017
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMonica Mita, Siqing Fu, Sarina Anne Piha-Paul, et al.
Melanoma Research|July 22, 2005
KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patientsFilip Janku, Jan Novotny, Ivan Julis, et al.
Investigational New Drugs|August 29, 2013
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatmentIgnacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignanciesBoaz Mendzelevski, Georg Ferber, Filip Janku, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Pageof 28

Showing results (61-70 of 277) with videos related to

Sort By:
Pageof 28
Plos One|August 15, 2014
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsYunyun Jiang, Vivek Subbiah, Filip Janku, et al.
Investigational New Drugs|April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerFilip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Cold Spring Harbor Molecular Case Studies|August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumorsShiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
Investigational New Drugs|February 15, 2017
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMonica Mita, Siqing Fu, Sarina Anne Piha-Paul, et al.
Melanoma Research|July 22, 2005
KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patientsFilip Janku, Jan Novotny, Ivan Julis, et al.
Investigational New Drugs|August 29, 2013
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatmentIgnacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Cancer Chemotherapy and Pharmacology|April 1, 2018
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignanciesBoaz Mendzelevski, Georg Ferber, Filip Janku, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Pageof 28